Lushang Freda Pharmaceutical Faces Financial Challenges Amid Declining Sales and High Debt

Lushang Freda Pharmaceutical Co., Ltd., a midcap player in the realty sector, has recently undergone an adjustment in its evaluation. This revision reflects a comprehensive analysis of various financial metrics and market conditions impacting the company. The company has faced notable challenges, including a decline in net sales, which reached CNY 807.27 million in the latest quarter, marking a significant low. Additionally, the operating profit was reported at CNY 11.23 million, with an operating profit margin of just 1.39%. Over the past five years, Lushang Freda has experienced a contraction in net sales at an annual rate of 17.30%, alongside an operating profit decline of 12.77%. The company's financial structure shows a high debt burden, indicated by a debt-to-equity ratio that raises concerns about its long-term sustainability. Despite generating a return on equity of 5.87%, the valuation remains high with a price-to-book ratio of 1.86. Furthermore, Lushang Freda has consistently underperformed against the benchmark, including the China Shanghai Composite, over the past three years. For those interested in tracking the latest developments, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.